Conmed vs Haemonetics
CNMD and HAE side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNMD and HAE compare
Haemonetics is the larger company, worth 3.8 times as much as Conmed ($5.5B against $1.5B).
On earnings, Conmed is cheaper: it trades at 20.4× trailing earnings, against 59.2× for Haemonetics.
Conmed grew revenue faster over the last twelve months (1.6% versus 0.44% for Haemonetics).
Haemonetics keeps more of each dollar of sales as profit, with a net margin of 7.1% compared with 5.4% at Conmed.
Conmed scores higher on the StockData Score (14 against 7 for Haemonetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNMD | HAE |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $5.5B |
| Share price | $49.35 | $121.34 |
| Change, 1 year | 14.1% | 64.2% |
| Change, 5 years | −63.5% | 134% |
| Beta (5Y) | 0.35 | 0.57 |
| Employees | 3,900 | – |
| StockData Score | ||
| Total score | 14 (better) | 7 |
| Valuation score | 6 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 3 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 20.4× (better) | 59.2× |
| P/S | 1.1× (better) | 4.1× |
| P/B | 1.4× (better) | 6.6× |
| EV/EBITDA | 16.5× (better) | 23.9× |
| P/FCF | 11.1× (better) | 19.0× |
| FCF yield | 9.0% (better) | 5.3% |
| Fair value | $67.98 | $69.95 |
| Margin of safety | 27.4% (better) | −73.5% |
| Growth | ||
| Revenue growth (TTM) | 1.6% (better) | 0.44% |
| Revenue growth, 5Y average | 9.8% (better) | 8.9% |
| Net income growth (TTM) | 14.6% (better) | −41.1% |
| EPS growth (TTM) | 18.0% (better) | −37.3% |
| EPS growth, 5Y average | 36.4% (better) | 5.8% |
| Profitability | ||
| Gross margin | 57.6% | 59.0% (better) |
| Operating margin | 9.9% | 11.9% (better) |
| Net margin | 5.4% | 7.1% (better) |
| FCF margin | 9.7% | 21.5% (better) |
| Return on equity | 7.1% | 11.2% (better) |
| Return on invested capital | 5.2% | 6.6% (better) |
| Financial health | ||
| Debt / equity | 0.77 (better) | 1.40 |
| Net debt / EBITDA | 5.66 | 3.52 (better) |
| Interest coverage | 4.1× | – |
| Current ratio | 1.49 | 3.08 (better) |
| Altman Z-score | 2.01 | 3.42 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Payout ratio | 8.4% | – |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | −5.6% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 114% | 109% |
| Held by insiders | 0.47% | 1.8% |
| Insider net buying, 12 months | $0 (better) | −$101K |
| Short interest, % of float | 6.3% | 8.1% |
Go deeper
- CNMD stock overview
- CNMD income statement
- CNMD valuation and score
- HAE stock overview
- HAE income statement
- HAE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.